Concepedia

Olaf Prien

OP

Statistics

Publications

9

Citations

384

H-Index

9

Active since

1997

Affiliations

Bayer (Germany)(Current)

Orion Corporation (Finland)

Olaf Prien is an author at Bayer (Germany) specializing in natural sciences, organic chemistry, and catalysis.

Top concepts

Publications per year

1997–2021

9

Publications

9

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Christian Zurth, Mikko Koskinen, Robert E. Fricke et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2019 · 94 citations · Full text

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal D. Shore, Christian Zurth, Robert E. Fricke et al. · Targeted Oncology · 2019 · 90 citations · Full text

From the Insoluble Dye Indirubin towards Highly Active, Soluble CDK2‐Inhibitors

Rolf Jautelat, Thomas Brumby, Martina Schäfer et al. · ChemBioChem · 2005 · 81 citations · Full text

, , +17

3,3‘-Dipyridyl BINOL Ligands. Synthesis and Application in Enantioselective Addition of Et<sub>2</sub>Zn to Aldehydes

Robert R. Milburn, Syed Muhammad Shakil Hussain, Olaf Prien et al. · Organic Letters · 2007 · 35 citations

Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug–Drug Interaction Potential

Marcus‐Hillert Schultze‐Mosgau, Joachim Höchel, Olaf Prien et al. · Clinical Pharmacokinetics · 2018 · 29 citations · Full text

1–5 of 9